The John Green Effect: Will Industry Be Influenced Again?

The Fault In Our Global Access To Medicines Practices

Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry. 

social media
• Source: Shutterstock

Advocacy groups recently used social media to sway the biopharma industry. And not only did the effort – which involved a high-profile influencer – alter a decade-long battle over access to tuberculosis products, but it may embolden other advocates to use social media to best companies at their own game.

More from Business Strategy

More from In Vivo

Podcast: JPM Tracked And Unpacked

 

In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.

M&A Takeoff May Be Delayed, Experts Predict

 

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

Genmab Has First Wholly Owned Antibodies In Phase III, Hunts For More

 
• By 

CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.